This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Defying Industry Trends, BBK Worldwide Expands Ownership From Within

NEWTON, Mass., March 21, 2013 /PRNewswire/ -- In an industry increasingly defined by mergers and acquisitions, BBK Worldwide (BBK) is bucking the trend by creating ownership opportunities from within. Celebrating 30 years, BBK remains one of the only independent and self-funded patient recruitment agencies, and is able to offer its global pharmaceutical and medical device clients levels of flexibility and creative innovation unmatched by its competitors. This history of vision and leadership has led BBK to name four additional principals who, together, will assume a minority ownership in the company. All long-serving employees, Matthew Kibby, Rob Laurens, Liz Ritchie, and Matthew Stumm have played key roles in shaping the company's success as the global leader in patient recruitment for the clinical R&D segment of the pharma, biotech, and medical device industries. As principals, they will partner with BBK's founding principals Joan F. Bachenheimer and Bonnie A. Brescia to maintain the company's core mission and values while driving growth in key market areas.

"These four individuals have made unyielding contributions to BBK over the years -- contributions that have brought innovation and definition to the patient recruitment marketplace as a whole," comments Joan F. Bachenheimer, founding principal, BBK Worldwide. "Their new roles will allow for expanded growth in critical business areas, ensuring that current and future customers benefit from the most strategic and sophisticated thinking in the industry."

Each newly named principal will focus their efforts on expanding their current management areas. Matthew Stumm will draw upon his creative vision to drive innovation for Agency320, BBK's partner company responsible for creative and media services. Rob Laurens will apply his 19 years of industry knowledge to advance patient recruitment training and industry best practices. Liz Ritchie, BBK's third longest-serving employee, will continue to manage corporate and legal services. Matthew Kibby will apply his innovative mindset to expanding and refining product offerings from BBK's technology partner TCN Technologies and its hallmark product TrialCentralNet SM.

Companies often turn to mergers and acquisitions as a corporate strategy for creating growth, however, often at the expense of innovation. BBK's current move represents a deliberate shift from this industry trend. "Over the past 10 years, BBK has been approached by several different organizations interested in taking an outside investment in BBK," comments Bonnie A. Brescia, founding principal, BBK Worldwide. "We've taken a different approach that values the commitment and dedication of our employees. Our business model reflects our commitment to, and appreciation for, our employees and for their hard work and investment. This dynamic model creates opportunities to expand ownership from within."

Guided by the law firm of Morse, Barnes-Brown & Pendleton, PC, BBK was able to create a new corporate structure that also has the potential to seamlessly expand ownership opportunities to other deserved employees within the company -- further ensuring the retention of key talent and the viability of the company moving forward. "We're thrilled to be able to connect employees to the success of the company with this new model that provides customers with the most experienced and sophisticated patient recruitment support in the industry," comments Bachenheimer.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs